Abstract P3-09-02: Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL
暂无分享，去创建一个
D. Berry | L. Esserman | N. Hylton | Minetta C. Liu | D. Yee | C. Yau | W. Symmans | H. Rugo | C. Isaacs | A. DeMichele | J. Boughey | A. Sanil | R. Nanda | K. Albain | A. Clark | E. Stringer-Reasor | T. Sanft | J. Perlmutter | A. Chien | A. Wallace | K. Kemmer | A. Elias | J. Lang | M. Melisko | R. Schwab | Amy Wilson | K. Kalinsky | P. Robinson | Janice M. Lu | Patricia K Haugen | S. Asare | Heather S. Han | R. Singhrao | L. Veer